

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO. FILING DATE ATTORNEY DOCKET NO. FIRST NAMED INVENTOR CONFIRMATION NO. 09/892,071 06/26/2001 Michael D. Pierschbacher P-LA 4798 4768 23601 7590 12/03/2003 EXAMINER CAMPBELL & FLORES LLP CHISM, BILLY D 4370 LA JOLLA VILLAGE DRIVE ART UNIT 7TH FLOOR PAPER NUMBER SAN DIEGO, CA 92122 1654

DATE MAILED: 12/03/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

	<del></del>		
		Application No.	Applicant(s)
Office Action Summary		09/892,071	PIERSCHBACHER ET AL.
		Examiner	Art Unit
		B. Dell Chism	1654
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status			
	Responsive to communication(s) filed on 11	September 2003.	
-		is action is non-final.	
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.		
Disposition of Claims			
4)⊠	Claim(s) <u>45-61</u> is/are pending in the application.		
	4a) Of the above claim(s) is/are withdrawn from consideration.		
5)	Claim(s) is/are allowed.		
6)⊠	Claim(s) <u>45-61</u> is/are rejected.		
7) 🗌	Claim(s) is/are objected to.		
8)[	Claim(s) are subject to restriction and	or election requirement.	
Application Papers			
9)☐ The specification is objected to by the Examiner.			
10)	10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.		
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).		
	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).		
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.			
Priority under 35 U.S.C. §§ 119 and 120			
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.			
	<ul> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> </ul>		
* See the attached detailed Office action for a list of the certified copies not received.  13) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet.  37 CFR 1.78.			
a) The translation of the foreign language provisional application has been received.			
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.			
Attachment(s)			
_	e of References Cited (PTO-892)	4) 🔲 Interview Summary	(PTO-413) Paper No(s)
2) 🔲 Notice	e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal F	Patent Application (PTO-152)

Application/Control Number: 09/892,071

Art Unit: 1654

#### **DETAILED ACTION**

This Office Action is in response to arguments filed 11 September 2003.

## Withdrawal of Objections and Rejections

The rejections and/or objections made in the prior office action filed 11 March 2003, which are not explicitly stated below, in original or modified form are withdrawn.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Applicants' arguments filed 11 September 2003 will be addressed to the extent that they pertain to the present grounds of rejection.

### Claim Rejections - 35 USC § 112

- 1. (Withdrawn) Rejection of claim 45, under 35 U.S.C. 112, second paragraph, for indefinite recitation of the phrase "other receptors" has been withdrawn in light of claim amendments deleting the phrase.
- 2. (Withdrawn) Rejection of claim 46 under 35 U.S.C. 112, second paragraph, for the depending from rejected claim 45 is withdrawn in light of claim amendments to claim 45.
- 3. (Withdrawn) The rejection of claims 46, 48, 50, 52, 54, 57, 59 and 61 under 35 U.S.C. 112, first paragraph, is withdrawn subsequent to Applicants' arguments and evidence, which were persuasive.

# Claim Rejections - 35 USC § 102

4. (Maintianed) Claims 45, 47, 49 and 51 remain rejected under 35 U.S.C. 102(b) as being anticipated by Hayman *et al*. As stated in the previous office action filed 11 March 2003, Hayman *et al*. teaches methods of using an RGD containing peptide that is conformationally

Application/Control Number: 09/892,071

Art Unit: 1654

restricted by the definition of the present specification. As stated in previous office action; "
...Applicants' specification discloses a conformationally restricted RGD sequence as provided
by cyclization, by inclusion into a constraining conformational structure, OR by providing an
additional chemical structure (see the specification at page 3, lines 9-14). The previous
arguments stands that Hayman et al. teaches a peptide compound that fits the conformational
restriction of the later definition requirement of the specification. The Applicants failed to
demonstrate that the additional amino acids to the RGD sequence of Hayman et al. do not
constitute "additional chemical structure[s]". Although new claims 55-61 specify "cyclic
peptide", the limitation does not obviate the anticipation of Hayman et al. of claims 45, 47, 49
and 51.

### **Double Patenting**

1. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

2. (Maintained in part/necessitated in part) Claims 45-61 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 45-52 and 61-68 of U.S. Patent No. 5,981,468. Although the conflicting claims are not identical, they are not patentably distinct from each other because of those reasons as set forth in the previous

Application/Control Number: 09/892,071

Art Unit: 1654

office action filed 11 March 2003. The *Double Patenting* rejection was not addressed by the Applicants and is further applied to the new claims 55-61 as necessitated by amendment.

#### Conclusion

3. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to B. Dell Chism whose telephone number is 703-306-5815. The examiner can normally be reached on 7:30 AM - 4:30 PM, Monday through Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached on 703-306-3220. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular communications and 703-308-4242 for After Final communications.

Art Unit: 1654

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

B. Dell Chism

01 December 2003

BRENDA BRUMBACK
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600